• LAST PRICE
    5.6800
  • TODAY'S CHANGE (%)
    Trending Up0.1300 (2.3423%)
  • Bid / Lots
    5.4900/ 1
  • Ask / Lots
    6.5000/ 3
  • Open / Previous Close
    5.5700 / 5.5500
  • Day Range
    Low 5.5101
    High 5.9400
  • 52 Week Range
    Low 2.6800
    High 8.2212
  • Volume
    385,871
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 5.55
TimeVolumeCAPR
09:32 ET2075.57
09:34 ET2005.5101
09:38 ET32955.6
09:39 ET2005.58
09:41 ET54945.65
09:45 ET2005.66
09:50 ET71605.65
09:52 ET43005.7
09:54 ET57015.7086
09:56 ET40045.72
09:57 ET8005.65
10:10 ET1005.72
10:14 ET7005.7
10:15 ET1005.72
10:17 ET112255.69
10:19 ET2005.66
10:21 ET26625.69
10:28 ET15005.62
10:30 ET42005.66
10:33 ET64005.625
10:35 ET52305.661
10:37 ET7005.67
10:39 ET5005.73
10:42 ET78235.765
10:46 ET48585.79
10:50 ET8005.825
10:51 ET20435.8465
10:55 ET56025.8201
10:57 ET143065.9006
11:00 ET33365.9099
11:09 ET44795.86
11:11 ET1005.8899
11:13 ET1005.8301
11:15 ET3005.83
11:26 ET1005.85
11:33 ET23165.87
11:36 ET7005.84
11:44 ET150565.87
11:51 ET34025.85
11:56 ET2215.8629
12:00 ET117325.81
12:05 ET1005.79
12:07 ET26095.76
12:09 ET3005.8
12:14 ET1005.82
12:16 ET99705.71
12:20 ET3005.77
12:25 ET7005.8
12:30 ET12255.77
12:32 ET2005.77
12:36 ET11005.78
12:43 ET15005.78
12:48 ET50005.7718
12:50 ET1605.7716
12:52 ET60545.7103
12:54 ET160495.7318
12:57 ET7855.7101
01:03 ET2005.73
01:08 ET19595.71
01:10 ET128505.62
01:12 ET16005.63
01:19 ET1005.68
01:21 ET2005.645
01:24 ET1005.65
01:26 ET2005.62
01:28 ET10015.7
01:32 ET62195.71
01:39 ET10475.7273
01:44 ET1005.75
01:48 ET3165.69
01:50 ET1005.75
01:51 ET2005.7
01:53 ET4075.73
01:55 ET26185.69
01:57 ET53535.6
02:00 ET47005.67
02:02 ET3755.61
02:04 ET7005.65
02:06 ET3505.645
02:08 ET1005.67
02:09 ET1005.67
02:11 ET58485.6
02:13 ET161155.6199
02:15 ET7005.64
02:22 ET1005.66
02:24 ET1475.67
02:26 ET2005.7
02:29 ET1005.69
02:31 ET111665.65
02:38 ET1005.66
02:40 ET1505.65
02:42 ET1005.66
02:44 ET1005.68
02:45 ET1005.67
02:47 ET1005.68
02:49 ET3225.68
02:51 ET1005.64
02:54 ET2005.67
02:56 ET1005.67
02:58 ET2005.67
03:02 ET42295.625
03:07 ET101005.58
03:09 ET1005.58
03:18 ET25145.61
03:20 ET5485.6
03:21 ET154345.68
03:23 ET6935.69
03:25 ET1005.71
03:27 ET3585.71
03:30 ET2005.71
03:32 ET14005.72
03:34 ET3085.72
03:36 ET3795.705
03:38 ET1005.72
03:39 ET2005.73
03:41 ET3005.75
03:43 ET17415.71
03:45 ET8465.73
03:48 ET31625.71
03:50 ET1385.705
03:52 ET7005.7
03:54 ET41815.71
03:56 ET25985.71
03:57 ET8385.71
03:59 ET54525.68
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCAPR
Capricor Therapeutics Inc
180.7M
-6.5x
---
United StatesCLLS
Cellectis SA
187.5M
-1.4x
---
United StatesFENC
Fennec Pharmaceuticals Inc
185.2M
185.4x
---
United StatesTLSI
TriSalus Life Sciences Inc
194.5M
-3.4x
---
United StatesCGEN
Compugen Ltd
194.3M
-11.5x
---
United StatesMDWD
Mediwound Ltd
151.4M
-11.8x
---
As of 2024-06-01

Company Information

Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.

Contact Information

Headquarters
8840 Wilshire Blvd, 2nd FloorBEVERLY HILLS, CA, United States 90211
Phone
310-358-3200
Fax
302-655-5049

Executives

Executive Chairman of the Board
Frank Litvack
President, Chief Executive Officer, Director
Linda Marban
Chief Financial Officer
Anthony Bergmann
Executive Vice President, General Counsel
Karen Krasney
Director
Paul Auwaerter

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$180.7M
Revenue (TTM)
$27.1M
Shares Outstanding
31.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
3.97
EPS
$-0.88
Book Value
$0.73
P/E Ratio
-6.5x
Price/Sales (TTM)
6.7
Price/Cash Flow (TTM)
---
Operating Margin
-96.53%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.